Bovine respiratory syncytial virus (BRSV) is a respiratory virus that infects mainly cattle, but can also infect sheep and goats. It can vary in its ability to cause disease, ranging from fatal to no clinical signs shown. BRSV can also make the animal more vunerable to secondary infections, where the virus weakens the immune system so that bacteria that are usually harmless can cause disease. BRSV is a single stranded RNA virus that belongs to the Paramyxoviridae family of viruses, genus Pneumovirus. It is closely related to human RSV.

Associated diseases:

BRSV causes bovine respiratory disease and is also a component of the bovine respiratory disease complex.

Clinical Signs:

  • Watery to thick mucus from nose/eyes
  • Increased temperature
  • Increased breathing rate with open mouth
  • Decreased appetite
  • Appear depressed
  • Reduced milk production
  • Dry cough and difficulty breathing
  • Frothy saliva
  • Trouble drinking

Disease spread:

The disease is spread by infected animal aerosols, direct contact and transmission through objects (fomites). In outbreaks, infection rate is high but the fatality rate can be 0–20%.

Disease prevalence:

BRSV is globally spread and has an economic impact on beef and dairy producers.  

Impact for Society – what are we doing?

BRSV is the most important primary viral cause of respiratory disease in young calves in the UK, affecting approximately 1.9 million calves each year, at a cost of £54 million. Research at the Institute is ongoing to find components of the virus that could be suitable for vaccine use and to investigate ways to boost protective immunity against BRSV whilst avoiding potentially damaging immune responses.


* Image by Dr. H. Craig Lyerla courtesy of Public Health Image Library (PHIL)

Research papers

Hagglund S, Naslund K, Svensson A, Lefverman C, Enul H, Pascal L, Siltenius J, Holzhauer M, Delabouglise A, Osterberg J, Alvasen K, Olsson U, Eleouet J-F, Riffault S, Taylor G, Rodriguez M J, Garcia Duran M, Valarcher J F (2022)

PLoS One 17 (9) , e0274332
Jean François Valarcher, Sara Hägglund, Katarina Näslund, Luc Jouneau, Ester Malmström, Olivier Boulesteix, Anne Pinard, Dany Leguéré, Alain Deslis, David Gauthier, Catherine Dubuquoy, Vincent Pietralunga, Aude Rémot, Alexander Falk, Ganna Shevchenko, Sara Bergström Lind, Claudia Von Brömssen, Karin Vargmar, Baoshan Zhang, Peter D. Kwong, María Jose Rodriguez, Marga Garcia Duran, Isabelle Schwartz-Cornil, Geraldine Taylor, Sabine Riffault (2021)

Vaccines 9 (3) , 236
Charleston B, Graham S P (2018)

Current Opinion in Virology 29 , 33-38
Hagglund S, Blodorn K, Naslund K, Vargmar K, Lind S B, Mi J, Arainga M, Riffault S, Taylor G, Pringle J, Valarcher J F (2017)

PLoS One 12 (10) , e0186594
Hagglund S, Hu K, Vargmar K, Pore L, Olofson A S, Blodorn K, Anderson J, Ahooghalandari P, Pringle J, Taylor G, Valarcher J F (2011)

Vaccine 29 (47) , 8719-8730


Trim content

® The Pirbright Institute 2024 | A company limited by guarantee, registered in England no. 559784. The Institute is also a registered charity.